Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease.
The purpose of this study was to estimate the net cost effect to Medicare of the increasing use of recombinant human erythropoietin (EPO) instead of red blood cell transfusions or androgens in the management of anemia for the approximately 100,000 hemodialysis patients in the U.S. End-Stage Renal Di...
Main Authors: | Powe, N, Griffiths, R, Bass, E |
---|---|
Format: | Journal article |
Language: | English |
Published: |
1993
|
Similar Items
-
Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients.
by: Powe, N, et al.
Published: (1993) -
Impact of erythropoietin on anemia in end-stage renal disease patients on hemodialysis
by: Bashaer M Muhammad-Baqir, et al.
Published: (2023-01-01) -
Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.
by: Powe, N, et al.
Published: (1992) -
A review of the first year of Medicare coverage of erythropoietin.
by: Griffiths, R, et al.
Published: (1994) -
The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients.
by: de Lissovoy, G, et al.
Published: (1994)